These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 16734851

  • 1. Prostate-specific antigen failure within 2 years of radical prostatectomy predicts overall survival.
    Hachiya T, Ichinose T, Hirakata H, Kawata N, Okada K, Takimoto Y.
    Int J Urol; 2006 Apr; 13(4):362-7. PubMed ID: 16734851
    [Abstract] [Full Text] [Related]

  • 2. Radical prostatectomy for clinical stage T3a disease.
    Freedland SJ, Partin AW, Humphreys EB, Mangold LA, Walsh PC.
    Cancer; 2007 Apr 01; 109(7):1273-8. PubMed ID: 17315165
    [Abstract] [Full Text] [Related]

  • 3. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U, Scattoni V, Freschi M, Briganti A, Salonia A, Gallina A, Colombo R, Karakiewicz PI, Rigatti P, Montorsi F.
    Eur Urol; 2008 Jul 01; 54(1):118-25. PubMed ID: 18314255
    [Abstract] [Full Text] [Related]

  • 4. Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy.
    Rogers CG, Khan MA, Craig Miller M, Veltri RW, Partin AW.
    Cancer; 2004 Dec 01; 101(11):2549-56. PubMed ID: 15470681
    [Abstract] [Full Text] [Related]

  • 5. Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy.
    Soergel TM, Koch MO, Foster RS, Bihrle R, Wahle G, Gardner T, Jung SH.
    J Urol; 2001 Dec 01; 166(6):2198-201. PubMed ID: 11696735
    [Abstract] [Full Text] [Related]

  • 6. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
    Sengupta S, Blute ML, Bagniewski SM, Inman B, Leibovich BC, Slezak JM, Myers RP, Zincke H.
    BJU Int; 2008 Jan 01; 101(2):170-4. PubMed ID: 18173824
    [Abstract] [Full Text] [Related]

  • 7. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy.
    Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H.
    J Urol; 2003 Nov 01; 170(5):1872-6. PubMed ID: 14532796
    [Abstract] [Full Text] [Related]

  • 8. Maximal tumor diameter and the risk of PSA failure in men with specimen-confined prostate cancer.
    Dvorak T, Chen MH, Renshaw AA, Loffredo M, Richie JP, D'Amico AV.
    Urology; 2005 Nov 01; 66(5):1024-8. PubMed ID: 16286117
    [Abstract] [Full Text] [Related]

  • 9. Risk stratification of high-grade prostate cancer treated with antegrade radical prostatectomy with intended wide resection.
    Yamamoto S, Kawakami S, Yonese J, Fujii Y, Tsukamoto T, Ohkubo Y, Komai Y, Ishikawa Y, Fukui I.
    Jpn J Clin Oncol; 2009 Jun 01; 39(6):387-93. PubMed ID: 19395463
    [Abstract] [Full Text] [Related]

  • 10. Radical prostatectomy for high-risk prostate cancer: biochemical outcome.
    Kawamorita N, Saito S, Ishidoya S, Ito A, Saito H, Kato M, Arai Y.
    Int J Urol; 2009 Sep 01; 16(9):733-8. PubMed ID: 19674167
    [Abstract] [Full Text] [Related]

  • 11. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy.
    Sengupta S, Myers RP, Slezak JM, Bergstralh EJ, Zincke H, Blute ML.
    J Urol; 2005 Dec 01; 174(6):2191-6. PubMed ID: 16280762
    [Abstract] [Full Text] [Related]

  • 12. Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8-10 cancers.
    Boorjian SA, Karnes RJ, Rangel LJ, Bergstralh EJ, Frank I, Blute ML.
    BJU Int; 2008 Feb 01; 101(3):299-304. PubMed ID: 17922854
    [Abstract] [Full Text] [Related]

  • 13. Predictors of short postoperative prostate-specific antigen doubling time for patients diagnosed during PSA era.
    Lin DD, Schultz D, Renshaw AA, Rubin MA, Richie JP, D'Amico AV.
    Urology; 2005 Mar 01; 65(3):528-32. PubMed ID: 15780370
    [Abstract] [Full Text] [Related]

  • 14. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy.
    Bastian PJ, Palapattu GS, Yegnasubramanian S, Lin X, Rogers CG, Mangold LA, Trock B, Eisenberger M, Partin AW, Nelson WG.
    Clin Cancer Res; 2007 Sep 15; 13(18 Pt 1):5361-7. PubMed ID: 17875764
    [Abstract] [Full Text] [Related]

  • 15. Prostate cancer disease-free survival after radical retropubic prostatectomy in patients older than 70 years compared to younger cohorts.
    Malaeb BS, Rashid HH, Lotan Y, Khoddami SM, Shariat SF, Sagalowsky AI, McConnell JD, Roehrborn CG, Koeneman KS.
    Urol Oncol; 2007 Sep 15; 25(4):291-7. PubMed ID: 17628294
    [Abstract] [Full Text] [Related]

  • 16. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.
    Delongchamps NB, Zerbib M, Mejean A, Rouach Y, Debre B, Peyromaure M.
    Can J Urol; 2009 Oct 15; 16(5):4813-9. PubMed ID: 19796456
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Radical prostatectomy: survival outcome and correlation to prostate-specific antigen levels.
    Oberpenning F, Hamm M, Schmid HP, Hertle L, Semjonow A.
    Anticancer Res; 2000 Oct 15; 20(6D):4969-72. PubMed ID: 11326649
    [Abstract] [Full Text] [Related]

  • 19. Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure.
    D'Amico AV, Chen MH, Roehl KA, Catalona WJ.
    J Clin Oncol; 2005 Aug 01; 23(22):4975-9. PubMed ID: 16051949
    [Abstract] [Full Text] [Related]

  • 20. Prostate specific antigen nadir determined using ultra-sensitive prostate specific antigen as a predictor of biochemical progression after radical prostatectomy in Japanese males.
    Kinoshita H, Kamoto T, Nishiyama H, Nakamura E, Matsuda T, Ogawa O.
    Int J Urol; 2007 Oct 01; 14(10):930-4; discussion 934. PubMed ID: 17880291
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.